Ticker Details
Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
IPO Date:	May 1, 2012
Sector:	Healthcare
Industry:	Drug Manufacturers
Market Cap:	$2.92B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.47 | 1.98%
Avg Daily Range (30 D):	$0.72 | 1.43%
Avg Daily Range (90 D):	$0.67 | 1.37%

Institutional Daily Volume
Avg Daily Volume:	.48M
Avg Daily Volume (30 D):	.6M
Avg Daily Volume (90 D):	.62M

Trade Size
Avg Trade Size (Sh.):	87
Avg Trade Size (Sh.) (30 D):	51
Avg Trade Size (Sh.) (90 D):	49

Institutional Trades
Total Institutional Trades:	4,634
Avg Institutional Trade:	$1.79M
Avg Institutional Trade (30 D):	$2.97M
Avg Institutional Trade (90 D):	$3.46M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.18M
Avg Closing Trade (30 D):	$5.83M
Avg Closing Trade (90 D):	$5.78M
Avg Closing Volume:	67.09K

News

Feb 23, 2026 @ 11:15 PM Supernus Pharmaceuticals to Participate in March I... Source: Na

Dec 16, 2025 @ 4:35 AM Supernus Stock Is Up 31% This Past Year but Still ... Source: Jonathan Ponciano

Jul 28, 2025 @ 12:25 PM Supernus Pharmaceuticals Announces Expiration of H... Source: Globe Newswire

Feb 11, 2025 @ 9:30 PM Supernus Pharmaceuticals to Host Conference Call a... Source: N/A

Nov 26, 2024 @ 10:00 PM Supernus to Participate in the 36th Annual Piper S... Source: N/A

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-.33	$-.8	$.4
Diluted EPS	$-.34	$-.8	$.4
Revenue	$681.54M	$192.1M	$165.45M
Gross Profit	$603.89M	$173.14M	$148.63M
Net Income / Loss	$-19.12M	$-45.12M	$22.5M
Operating Income / Loss	$-36.94M	$-60.23M	$12.14M
Cost of Revenue	$77.65M	$18.97M	$16.83M
Net Cash Flow	$121.15M	$8.11M	$28.86M
PE Ratio